GT Biopharma, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Michael Martin Breen
- Full Time Employees
- 1
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 8000 Marina Boulevard San Francisco CA United States of America 94005
- IPO Date
- Mar 27, 2018
- CIK
- 0000109657
- Website
- gtbiopharma.com
- Similar Companies
- Business
- GT Biopharma, Inc. (NASDAQ: GTBP) is a clinical-stage biopharmaceutical company focused on developing and commercializing immuno-oncology therapies based on its proprietary Tri-specific Killer Engager (TriKE) platform, which engages the CD16 receptor on natural killer (NK) cells for tumor-specific targeting and incorporates IL-15 to promote NK cell proliferation and activation; its lead product candidates include GTB-3650, a second-generation camelid nanobody TriKE in Phase 1 clinical testing for CD33-positive leukemias such as acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), with enrollment advanced to Cohort 4 at 10 µg/kg/day as of November 2025 showing evidence of NK cell expansion and no major tolerability issues; GTB-5550, a dual-camelid nanobody TriKE targeting B7H3-positive solid tumors including breast, lung, ovarian, head and neck, pancreatic, bladder, and prostate cancers, with clinical material manufactured and an investigational new drug (IND) application planned for submission in late December 2025 or January 2026 to enable subcutaneous dosing trials; and GTB-7550, a TriKE in preclinical development for CD19-positive lymphoid malignancies such as lymphoma and chronic lymphocytic leukemia as well as autoimmune diseases like lupus, with manufacturing bids under evaluation for clinical material production in 2026. The company previously discontinued its first-generation GTB-3550 TriKE following Phase 1 proof-of-concept data in AML and MDS, shifting focus to the more potent second-generation platform utilizing camelid nanobodies and wild-type IL-15. Founded in 1965 and headquartered at 505 Montgomery Street, 10th Floor, in San Francisco, California, GT Biopharma holds an exclusive worldwide license from the University of Minnesota for its TriKE technology and conducts operations primarily in the United States, targeting hematologic malignancies, solid tumors, and autoimmune disorders. Recent developments include a May 2025 financing round that funded resumption of GTB-5550 final development and continuation of the GTB-3650 Phase 1 trial, with Cohort 3 safety clearance in July 2025, initial biomarker data releases throughout 2025 indicating immune activation, and plans for comprehensive GTB-3650 updates in Q1 2026 alongside GTB-5550 IND progress.
GT Biopharma Provides Update on Pipeline Discovery Activities from Newly Implemented AI-Based Technological Initiatives
The $13 Million Company Teaching the Immune System to Hunt Cancer
B7-H3 Becomes The Hottest Antigen In Oncology, And One NK Engager Enters Clinic
GT Biopharma Reports First Quarter 2026 Financial Results
GT Biopharma Announces First Patient Dosed in Phase 1 Trial of GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors
EXCLUSIVE: GT Biopharma Begins Testing Of Lead Solid Tumor Drug Candidate Across Multiple Cancer Types
Head to Head Contrast: Cogent Biosciences (NASDAQ:COGT) versus GT Biopharma (NASDAQ:GTBP)
GT Biopharma (GTBP) Upgraded to Buy: Here's What You Should Know
GT Biopharma (GTBP) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
GT Biopharma to Participate in the 38th Annual Roth Conference
GT Biopharma Reports Full Year 2025 Financial Results
GT Biopharma to Present at the Centurion One Capital 9th Annual Toronto Growth Conference
GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-5550 TriKE®, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors Expressing B7-H3
GT Biopharma Announces IND Submission for GTB-5550 TriKE®, a B7-H3-targeted natural killer (NK) cell engager for B7-H3 expressing solid tumor cancers
EXCLUSIVE: GT Biopharma Plans 2026 Trial For New Cancer Treatment
Precision's Payoff: Targeted Therapies Drive $131B Solid Tumor Market Surge
Immunotherapies Replacing Chemotherapy as Blood Cancer Market to Hit $13B by 2030
Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points
GT Biopharma, Inc. (NASDAQ:GTBP) Offers Near-Term Catalyst Opportunity with Advancing Phase 1 Trials
GT Biopharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update